Study offers hope to pregnant women with HIV

11/6/2007 | France 24

Adding single doses of tenofovir and emtricitabine to the standard single dose niverapine to treat HIV-infected women during labor reduces resistance to non-nucleoside reverse transcriptase inhibitor drugs, a new study found. By reducing the maternal niverapine resistance, it becomes possible to treat HIV-infected babies with commonly used medications.

View Full Article in:

France 24

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT